AMXT 1501

Drug Profile

AMXT 1501

Alternative Names: AMXT 1501 dicaprate; AMXT1501

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aminex Therapeutics
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Mar 2017 Preclinical trials in Cancer in USA before March 2017 (PO)
  • 17 Mar 2017 Aminex Therapeutics plans a phase I trial for Cancer (In healthy volunteers) in USA (NCT03077477)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top